JP2021533152A5 - - Google Patents
Info
- Publication number
- JP2021533152A5 JP2021533152A5 JP2021506326A JP2021506326A JP2021533152A5 JP 2021533152 A5 JP2021533152 A5 JP 2021533152A5 JP 2021506326 A JP2021506326 A JP 2021506326A JP 2021506326 A JP2021506326 A JP 2021506326A JP 2021533152 A5 JP2021533152 A5 JP 2021533152A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidine
- compound
- nitrooxy
- ethyl
- methyl
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024125823A JP2024150732A (ja) | 2018-08-06 | 2024-08-01 | 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18187482.7 | 2018-08-06 | ||
| EP18187482 | 2018-08-06 | ||
| EP18210147.7 | 2018-12-04 | ||
| EP18210147 | 2018-12-04 | ||
| PCT/EP2019/070597 WO2020030489A1 (en) | 2018-08-06 | 2019-07-31 | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125823A Division JP2024150732A (ja) | 2018-08-06 | 2024-08-01 | 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533152A JP2021533152A (ja) | 2021-12-02 |
| JP2021533152A5 true JP2021533152A5 (https=) | 2022-08-08 |
| JPWO2020030489A5 JPWO2020030489A5 (https=) | 2022-08-08 |
| JP7596257B2 JP7596257B2 (ja) | 2024-12-09 |
Family
ID=67539493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506326A Active JP7596257B2 (ja) | 2018-08-06 | 2019-07-31 | 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 |
| JP2024125823A Pending JP2024150732A (ja) | 2018-08-06 | 2024-08-01 | 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125823A Pending JP2024150732A (ja) | 2018-08-06 | 2024-08-01 | 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11980618B2 (https=) |
| EP (1) | EP3833395A1 (https=) |
| JP (2) | JP7596257B2 (https=) |
| KR (1) | KR102836746B1 (https=) |
| CN (2) | CN119350347A (https=) |
| AU (1) | AU2019319004B2 (https=) |
| BR (1) | BR112021001950A2 (https=) |
| CA (1) | CA3108551A1 (https=) |
| MX (2) | MX2021001503A (https=) |
| TW (1) | TWI839375B (https=) |
| WO (1) | WO2020030489A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7708771B2 (ja) * | 2020-02-05 | 2025-07-15 | ニコックス エス．エー． | 緑内障及び高眼圧症の処置のための組成物 |
| CN111217834B (zh) * | 2020-02-21 | 2021-10-26 | 维眸生物科技（上海）有限公司 | Rock激酶抑制剂的硝基氧衍生物 |
| WO2022022669A1 (en) * | 2020-07-30 | 2022-02-03 | Biofront Therapeutics (Beijing) Co., Ltd. | Dual-functional compounds and methods of use |
| KR102731727B1 (ko) * | 2020-07-30 | 2024-11-20 | 바이오프런트 쎄라퓨틱스 (베이징) 컴퍼니 리미티드 | 이중-기능성 화합물 및 이의 사용 방법 |
| CN116456963A (zh) * | 2020-11-02 | 2023-07-18 | 尼科斯股份有限公司 | 用于治疗干性年龄相关性黄斑变性、地图状萎缩和青光眼相关性神经变性的no-pde5抑制剂 |
| UY39509A (es) * | 2020-11-09 | 2022-01-31 | Ildong Pharmaceutical Co Ltd | Compuestos inhibidores de la pde-5 y/o la pde-6 donantes de óxido de nitrógeno, y usos de estos |
| WO2023005180A1 (en) * | 2021-07-30 | 2023-02-02 | Biofront Therapeutics (Beijing) Co., Ltd. | Dual-functional compounds and methods of use |
| JP2024541626A (ja) | 2021-12-02 | 2024-11-08 | ニコックス エス．エー． | 一酸化窒素放出ホスホジエステラーゼ５阻害剤を含有する眼科用医薬組成物及びその製造方法 |
| EP4233867B1 (en) | 2022-02-24 | 2025-09-03 | Nicox SA | Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60149521A (ja) | 1984-01-18 | 1985-08-07 | Eisai Co Ltd | 高眼圧・緑内障治療・予防用点眼剤 |
| US4975428A (en) | 1988-05-31 | 1990-12-04 | Iolab Corporation | Treatment of glaucoma using phosphodiesterase inhibitors |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| IL137429A0 (en) | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
| EP1219609B1 (en) | 1999-09-16 | 2007-04-04 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogenous six-membered ring compounds |
| KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
| US20020168424A1 (en) | 2002-07-31 | 2002-11-14 | Dr. Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| WO2008075152A1 (en) * | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension |
| US7993616B2 (en) | 2007-09-19 | 2011-08-09 | C-Quest Technologies LLC | Methods and devices for reducing hazardous air pollutants |
| ES2393049T3 (es) | 2008-02-07 | 2012-12-18 | Nicox S.A. | Compuestos donantes de óxido nítrico |
| EP2398761A4 (en) * | 2009-02-18 | 2015-11-04 | Bezwada Biomedical Llc | CONTROLLED RELEASE OF NITRIC OXIDE AND MEDICINES FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS |
| CN102498088A (zh) * | 2009-09-15 | 2012-06-13 | 帝斯曼知识产权资产管理有限公司 | 硝基氧基酯及其制备和用途 |
| AU2010330813B2 (en) * | 2009-12-18 | 2016-04-28 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating peripheral vascular disease |
| US9446015B2 (en) | 2012-10-23 | 2016-09-20 | Nicox Science Ireland | Quinone based nitric oxide donating compounds for ophthalmic use |
| EP2826491A1 (en) * | 2013-07-15 | 2015-01-21 | Nicox Science Ireland | Ophthalmic compositions containing a nitric oxide donor |
| TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| ES2632808T3 (es) | 2014-09-04 | 2017-09-15 | Nicox Science Ireland | Compuestos de carnosina donadores de óxido nítrico |
| US10610509B2 (en) | 2014-11-19 | 2020-04-07 | Nicox S.A. | Combinations of prostaglandins and nitric oxide donors |
| US10280138B2 (en) * | 2015-03-31 | 2019-05-07 | Nicox S.A. | Nitric oxide donating derivatives of fluprostenol |
| US10047047B2 (en) | 2015-03-31 | 2018-08-14 | Nicox S.A. | Nitric oxide donating derivatives of latanoprost free acid |
| EP3088388A1 (en) * | 2015-04-30 | 2016-11-02 | NicOx S.A. | Nitric oxide donating derivatives of prostaglandins |
| PL3377495T3 (pl) * | 2015-11-16 | 2022-05-16 | Topadur Pharma Ag | Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania |
| KR102670626B1 (ko) | 2017-05-22 | 2024-05-29 | 토파두르 파마 아게 | 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도 |
-
2019
- 2019-07-31 JP JP2021506326A patent/JP7596257B2/ja active Active
- 2019-07-31 CN CN202411482883.4A patent/CN119350347A/zh active Pending
- 2019-07-31 KR KR1020217006735A patent/KR102836746B1/ko active Active
- 2019-07-31 CN CN201980052271.2A patent/CN112566670B/zh active Active
- 2019-07-31 AU AU2019319004A patent/AU2019319004B2/en active Active
- 2019-07-31 BR BR112021001950-2A patent/BR112021001950A2/pt unknown
- 2019-07-31 US US17/265,134 patent/US11980618B2/en active Active
- 2019-07-31 MX MX2021001503A patent/MX2021001503A/es unknown
- 2019-07-31 EP EP19749305.9A patent/EP3833395A1/en active Pending
- 2019-07-31 WO PCT/EP2019/070597 patent/WO2020030489A1/en not_active Ceased
- 2019-07-31 CA CA3108551A patent/CA3108551A1/en active Pending
- 2019-08-02 TW TW108127595A patent/TWI839375B/zh active
-
2021
- 2021-02-05 MX MX2023012941A patent/MX2023012941A/es unknown
-
2024
- 2024-03-22 US US18/614,143 patent/US20240245684A1/en active Pending
- 2024-08-01 JP JP2024125823A patent/JP2024150732A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533152A5 (https=) | ||
| JP7249374B2 (ja) | 眼疾患を処置するための組成物、製剤、および方法 | |
| AU2016204410B2 (en) | Methods for treating vascular leak syndrome | |
| JP2013531063A (ja) | 二官能基Ｒｈｏキナーゼ阻害化合物、組成物およびその使用 | |
| US20100022590A1 (en) | Novel compounds | |
| WO2012015760A1 (en) | Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms | |
| JPWO2020030489A5 (https=) | ||
| KR102792934B1 (ko) | 세페타프로스트와 Rho 키나아제 저해제의 조합 의약 | |
| WO2019124489A1 (ja) | セペタプロストとｅｐ２アゴニストとの組み合わせ医薬 | |
| RU2021104718A (ru) | Ингибитор фосфодиэстеразы 5 типа, высвобождающий оксид азота | |
| JP2008540427A (ja) | 置換β−ラクタム及び医薬におけるその使用 | |
| JP2017525735A5 (https=) | ||
| US8609658B2 (en) | N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof | |
| JPWO2019124487A1 (ja) | オミデネパグの組合せ | |
| US9340534B2 (en) | Compounds and methods for treating ocular diseases | |
| WO2026027718A1 (en) | Cxcl8 inhibitors for use in the treatment of ocular graft-versus-host disease | |
| AU663595B2 (en) | Morpholine and thiomorpholine tachykinin receptor antagonists | |
| US8299068B2 (en) | Therapeutically active cyclopentanes | |
| WO2005108396A1 (ja) | 角結膜障害治療剤 | |
| JP2005350451A (ja) | 角結膜障害治療剤 | |
| JPWO2022090379A5 (https=) | ||
| WO2012165314A1 (ja) | アミド化合物 | |
| WO2002048096A1 (en) | Hydrazone derivatives and use thereof in medicines |